Overview

A Study in Migraine Prevention

Status:
Terminated

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to measure the change in frequency of migraine attacks per 28 days in migraine patients being treated orally with LY2300559 for 12 weeks.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company